| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
15,703 |
2,931 |
$185K |
| 87481 |
|
12,491 |
2,412 |
$156K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
5,752 |
4,064 |
$100K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
3,509 |
2,407 |
$51K |
| 87511 |
|
2,598 |
1,581 |
$29K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
3,294 |
1,760 |
$20K |
| 87653 |
|
1,450 |
1,189 |
$20K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
3,481 |
2,376 |
$19K |
| 87529 |
|
1,347 |
404 |
$16K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
1,046 |
909 |
$11K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
1,942 |
1,700 |
$8K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
55 |
50 |
$3K |
| 88342 |
|
53 |
40 |
$638.86 |
| 88312 |
|
190 |
117 |
$392.24 |
| 88141 |
|
51 |
43 |
$381.81 |
| 87625 |
|
19 |
16 |
$133.90 |
| G0145 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision |
279 |
227 |
$21.90 |
| G0476 |
Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test |
74 |
61 |
$19.44 |
| 87563 |
|
370 |
199 |
$0.00 |